BCL2 and Miyoshi myopathy: On the other hand, enforced expression of tumor suppressor miR-34a exerted a strong anti-MM activity through BCL2, CDK6, and NOTCH1 targeting both in vitro an in vivo in the SCID-synth-hu model of MM, which recapitulates the disease within its BM milieu [110,111].